In this review:
SGLT-2 inhibitors and major adverse CV event risk
Proposed NZ vs. US/European criteria for SGLT-2 inhibitors/GLP-1 agonists
Central fatness and risk of all-cause mortality
SGLT-2 inhibitors in HF with reduced ejection fraction
SGLT-2 inhibitors and DKA risk Intrauterine diabetes exposure and subsequent CV disease risk
Precision medicine in type 2 diabetes
Equivalence of age/diabetes duration to glycaemic control, relative to complications risk
SGLT-2 inhibitors for type 1 diabetes
Metformin for type 2 diabetes during pregnancy
Please login below to download this issue (PDF)